What is Noble Financial’s Estimate for MariMed Q1 Earnings?

MariMed Inc. (OTCMKTS:MRMD) – Equities researchers at Noble Financial issued their Q1 2026 earnings per share estimates for shares of MariMed in a report released on Monday, March 16th. Noble Financial analyst J. Gomes expects that the company will earn ($0.01) per share for the quarter. Noble Financial also issued estimates for MariMed’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.02) EPS and FY2027 earnings at ($0.02) EPS.

Separately, Zacks Research raised shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, MariMed has a consensus rating of “Moderate Buy”.

MariMed Price Performance

Shares of OTCMKTS MRMD opened at $0.08 on Tuesday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 0.38 and a current ratio of 1.00. The firm has a fifty day moving average of $0.09 and a 200 day moving average of $0.11. The firm has a market cap of $31.05 million, a PE ratio of -2.62 and a beta of 1.11. MariMed has a one year low of $0.07 and a one year high of $0.23.

MariMed Company Profile

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.